Sinovac Biotech (SVA) director discloses 70,000 common shares

Rhea-AI Filing Summary

SINOVAC BIOTECH LTD director Simon Anderson filed an initial ownership report showing he directly holds 70,000 common shares. This Form 3 does not record a new purchase or sale; it simply discloses his existing stake in the company’s common shares, par value $0.001 per share.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

ANDERSON SIMON

(Last) (First) (Middle)

6734 DUFFERIN AVENUE

(Street)

WEST VANCOUVER V7W 2K2

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
SINOVAC BIOTECH LTD [ SVA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common shares, par value $0.001 per share	70,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Jia Zhao, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Simon Anderson’s Form 3 filing for SINOVAC BIOTECH LTD (SVA) disclose?

The Form 3 filing discloses that director Simon Anderson directly owns 70,000 common shares of SINOVAC BIOTECH LTD. It is an initial ownership report, providing transparency about his existing stake rather than announcing a new transaction or change in holdings.

How many SINOVAC BIOTECH LTD (SVA) shares does director Simon Anderson report owning?

Simon Anderson reports direct ownership of 70,000 common shares of SINOVAC BIOTECH LTD. This figure represents his total reported holdings following the reported position, giving investors a clear view of his stake as a company director at the time of the filing.

Does the SINOVAC BIOTECH LTD (SVA) Form 3 show Simon Anderson buying or selling shares?

No, the Form 3 does not show Simon Anderson buying or selling shares. It classifies the entry as a holding, meaning the filing simply reports his existing 70,000-share position rather than documenting a new purchase, sale, or other transaction in the company’s stock.

What type of security is reported in Simon Anderson’s SINOVAC BIOTECH LTD (SVA) Form 3?

The filing reports ownership of common shares of SINOVAC BIOTECH LTD with a par value of $0.001 per share. These are standard equity securities representing ownership in the company, and the filing lists 70,000 such common shares as directly held by the director.

Is Simon Anderson’s 70,000-share position in SINOVAC BIOTECH LTD (SVA) held directly or indirectly?

The 70,000 common shares are reported as held directly by Simon Anderson. The ownership code is shown as direct, and no additional nature-of-ownership details or indirect holding structures, such as trusts or entities, are indicated in the provided Form 3 information.